NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
Luca Mologni(University of Milano-Bicocca), Carlo Gambacorti‐Passerini(University of Milano-Bicocca)
Cited by 33
Related Papers
Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation
|The EMBO Journal|2007|214
Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK
|Cancer Medicine|2015|88
Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase
|Journal of Biological Chemistry|2007|75
Inhibition of RET tyrosine kinase by SU5416
|Journal of Molecular Endocrinology|2006|54